ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PBYI Puma Biotechnology Inc

5.02
0.14 (2.87%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Puma Biotechnology Inc NASDAQ:PBYI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.14 2.87% 5.02 4.27 5.16 5.11 4.87 4.87 167,412 22:16:11

Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020

06/05/2020 9:20pm

Business Wire


Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Puma Biotechnology Charts.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will provide an overview of the Company at 3:40 p.m. EDT on Wednesday, May 13, at the BofA Securities Health Care Conference 2020. The conference will be held in a virtual meeting format.

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200 david.schull@russopartnersllc.com maggie.beller@russopartnersllc.com

1 Year Puma Biotechnology Chart

1 Year Puma Biotechnology Chart

1 Month Puma Biotechnology Chart

1 Month Puma Biotechnology Chart

Your Recent History

Delayed Upgrade Clock